25 C
Vientiane
Tuesday, November 4, 2025
spot_img
Home Blog Page 275

Digital Edge Secures Financing to Continue Expansion in Indonesia

JAKARTA, Indonesia, Oct. 8, 2025 /PRNewswire/ — Digital Edge (Singapore) Holdings Pte. Ltd. (“Digital Edge”), one of Asia’s fastest-growing data center platforms backed by global infrastructure investor Stonepeak, today announced the successful close of an IDR 5.5 trillion (USD 325 million) corporate facility from PT Bank Central Asia Tbk (BCA).

The corporate facility is provided to Digital Edge’s Indonesia platform, comprising the controlled subsidiaries, PT Indointernet Tbk (“Indonet”) and wholly owned subsidiary PT Ekagrata Data Gemilang (“EDGE DC”).

The proceeds from the facility will be used to support Digital Edge’s new build expansion in the Jakarta metro, refinance existing BCA facility and fund completion of the final phase of the 23MW state-of-the-art EDGE2 site. EDGE2 is strategically located in Jl. Kuningan Mulia, South Jakarta and is one of the most energy efficient data center in the Jakarta metro, achieving a market leading annualized PUE (Power Usage Effectiveness) of 1.24.

“We are delighted to be again partnering with BCA on this financing, as we continue to expand in this important and high-growth market. This facility will support our continued development of sustainable and market leading digital infrastructure to the world’s fourth most populous country,” said Jonathan Walbridge, Digital Edge’s Chief Financial Officer.

Rudy Susanto, Director Corporate of BCA, emphasized full support for Indonet’s expansion plans, commenting, “BCA sees Indonesia’s digital economy growth as a significant opportunity that must be supported by strong technology infrastructure. We believe Indonet and EDGE DC have the proven track record and capabilities to meet these needs. Through this financing facility, we hope to contribute to accelerating national digital transformation,” said Rudy.

About Digital Edge

Headquartered in Singapore, Digital Edge is a trusted and forward-looking data center platform company, established to transform digital infrastructure in Asia. Through building and operating state-of-the-art, energy-efficient data centers rich with connectivity options, Digital Edge aims to bring new colocation and interconnect options to the Asian market, making infrastructure deployment in the region easy, efficient and economical.

Backed by leading alternative investment firm Stonepeak, Digital Edge has established itself as a market-leading pan-Asia data center platform. The company provides data center and fiber services across nine countries in Asia Pacific, with more than 1.1GW of secured IT power. You can visit the company’s website at www.digitaledgedc.com

Cebu Pacific Launches 10.10 Seat Sale for 2026 Getaways

MANILA, Philippines, Oct. 8, 2025 /PRNewswire/ — Cebu Pacific (PSE: CEB), the Philippines’ leading carrier, gives travelers the chance to unpack happy holiday trips for 2026 as it launches its Super Seat Fest in time for 10.10 festivities.

From October 7 to 12, guests from Taiwan can book flights to Manila for as low as TWD 10 one-way base fare, exclusive of fees and surcharges. The travel period runs from March 1 to September 30, 2026, perfect for travelers mapping out their next vacation in the Philippines.

In Manila, guests can immerse themselves in history by strolling through Intramuros, the centuries-old walled city, and explore the National Museum Complex, which houses collections that highlight the country’s art, heritage, and biodiversity.

From Manila, travelers can also connect to 27 other domestic destinations, such as Iloilo and Cebu. In Iloilo, visitors can enjoy local specialties such as batchoy (noodle soup with pork ingredients) and pancit molo (wonton soup), or take a short trip to Guimaras Island, famous for its mangoes and beaches.  

Cebu invites visitors with its famous lechon (roasted pig) and fresh seafood, best enjoyed before an island-hopping tour or while relaxing on white-sand beaches. From Cebu, travelers can connect directly to Palawan to admire El Nido’s limestone cliffs and lagoons, or to Port Barton (San Vicente), home to the country’s longest white-sand beach solely served by CEB.

With the airline’s widest domestic reach, travelers can start their own journey to happiness in the Philippine capital or connect to the airline’s other key regional hubs such as Clark, Cebu, Iloilo and Davao, for faster inter-island access within the country.

CEB operates in 37 domestic and 26 international destinations spread across Asia, Australia, and the Middle East.

CEB offers various payment options, including credit or debit cards and e-wallets, to book flights and buy add-ons.

Book your flights now at www.cebupacificair.com.

Our social media handles:

Facebook: Cebu Pacific Air
X: @CebuPacificAir
Instagram: cebupacificair

CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology

SHANGHAI, Oct. 8, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of CT071 (an autologous CAR T-cell product targeting GPRC5D) for the treatment of relapsed/refractory multiple myeloma (R/R MM) in an investigator-initiated trial (NCT05838131) have been published in The Lancet Haematology. The article was titled “GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial”.

This trial aimed to assess the safety, preliminary activity of CT071 in R/R MM. 20 patients received CT071 infusion. Patients had received a median of 5 prior lines of therapy (IQR 3.0-6.5); 19 (95%) were double-class refractory, 13 (65%) were triple-class refractory, 5 (25%) were penta-drug refractory, 10 (50%) had received autologous stem cell transplantation (ASCT), and 5 (25%) had relapsed after CAR T-cell therapies targeting BCMA or BCMA/CD19. Four (20%) patients had extramedullary disease (EMD), 14 (70%) had ≥1 high-risk cytogenetics and 19 (95%) had a Revised International Staging System (R-ISS) 2 or 3 disease at baseline.

No dose-limiting toxicities (DLTs) were observed. The recommended phase 2 dose was determined at 0.1×106 CAR T cells/kg. Cytokine release syndrome occurred in 12 patients (60%), all graded as 1 or 2. No Grade ≥3 cytokine release syndrome (CRS) occurred. One patient (5%) experienced Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS). No treatment-related deaths occurred.

With a median follow-up of 10.71 months (IQR 6.13-12.02), the objective response rate (ORR) was 100% (95%CI, 83.2-100). 10 (50%) patients achieved stringent complete response (sCR), 4 (20%) had very good partial response (VGPR) and 6 (30%) had partial response (PR). One patient with a large EMD (125 mm×99 mm at baseline) achieved a 67.6% reduction at month 10 with ongoing PR. All 5 patients previously treated with an anti-BCMA CAR T (n=1) or anti-BCMA/CD19 CAR T (n=4) responded; 2 achieved PR, 1 achieved VGPR and 2 achieved sCR. 18 of 20 (90%) evaluable patients achieved MRD negativity at 10−6 including all 10 with CR or sCR. Median time to MRD negativity was 29 days (IQR 29-29). Median duration of response (DoR), progression-free survival (PFS) and overall survival (OS) were not reached. The data cutoff for all analyses was December 9, 2024.

About CT071
CT071 is a CAR T-cell therapy candidate developed utilizing the proprietary CARcelerate® platform targeting GPRC5D for the treatment of relapsed/refractory multiple myeloma (R/R MM) or plasma cell leukemia (PCL). Initiated trials include an investigator-initiated trial for R/R MM or PCL in China (NCT05838131), and an investigator-initiated trial for newly diagnosed multiple myeloma (NDMM) in China (NCT06407947).

About CARsgen Therapeutics Holdings Limited
CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements
All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

 

Financing Asia’s Future: IJGlobal’s Infrastructure Finance Forum (IFF): Asia 2025 comes to Singapore

SINGAPORE, Oct. 8, 2025 /PRNewswire/ — Taking place on 18 & 19 November 2025 at The Westin hotel in Singapore, IFF Asia will focus on bridging the region’s infrastructure financing gap in high-growth markets – showcasing investable projects and fostering collaboration among investors, developers and financiers.

“IFF Asia is built by investors, for investors. We will accelerate the projects that define the region’s next decade.” – Manju Dalal, Editor & APAC Head, IJGlobal

Agenda highlights include:  

  • The energy transition: exploring the investment opportunities across renewables and the technologies helping to accelerate deployment, from green hydrogen to storage and hybrid solutions.
  • Innovative financing: focusing on blended and sustainable structures in action, balancing de-risking with returns and the role of green bonds, SLLs and ESG frameworks. 
  • Financing the data-centre boom: deep-diving into the pipeline outlook, hyperscale-driven growth, mid-market roles, and the clean-power/offtake solutions emerging across APAC. 
  • Debt & private credit: a view on lenders’ capacity by sector, evolving pricing, and where direct lenders are prepared to commit capital in the year ahead.  
  • Building resilient assets: examining practical approaches to risk allocation and structures that hold up under geopolitical stress. 
  • Market opportunities: in-depth analysis of local markets across ASEAN, Northeast Asia, and Australia, with takeaways from live and recent transactions. 

Confirmed speakers include leaders from JERA Asia, Keppel, Acciona Energía, Siemens Bank, Pentagreen Capital, Octopus Energy Generation, AirTrunk, Marubeni, Brookfield, GIC, KKR, ESR Group, BluPine Energy, Infrastructure Asia, Actis, TotalEnergies, HSBC, the World Bank, and many more. 

IJGlobal’s editorial team, comprising Manju Dalal, Angus Leslie Melville and Ila Patel, will chair and moderate the conference.

Green Street’s Cedrik Lachance, EVP, Director of Research is also set to moderate the Australian energy and infrastructure market panel. 

IFF Asia 2025 will examine capital deployment, financing structures, and project pipelines across the APAC region, with a focus on execution. It convenes investors, sponsors and lenders for focused sessions on risk allocation, returns and delivery. Full details and registration are available on the event website.  

About IJGlobal:
IJGlobal is a single source of data, intelligence and analysis covering all aspects of the international infrastructure and energy finance industry. IJGlobal delivers news, transaction and investor/fund data, and events for global infrastructure to market participants worldwide, and through a comprehensive database that encompasses all infrastructure transaction participants, exclusive daily news, live League Table rankings, and more. IJGlobal is headquartered in London and was founded in 1997. For more information, please visit https://hub.ijglobal.com/.

About Green Street
Green Street is a forward-thinking real assets company at the forefront of transforming the commercial real estate market with cutting-edge predictive analytics, data-driven insights, and actionable intelligence. With over 40 years of expertise, Green Street empowers investors, lenders, and stakeholders across the U.S., Canada, Europe, and Australia to make optimized investment and strategic decisions. 

Media contact:

greenstreet@nextpr.com

TTS Group Pte Ltd Wins Dual Awards at the Asia Pacific Enterprise Awards 2025 Regional Edition

SINGAPORE, Oct. 7, 2025 /PRNewswire/ — TTS Group Pte Ltd has been honoured with two awards at the Asia Pacific Enterprise Awards 2025 Regional Edition: Its Managing Director and Board Chairman, Kelvin Foo Yong Kiang, took home the Master Entrepreneur Award while the company was honored with the Inspirational Brand Award for its outstanding contributions to intelligent transport solutions.

Kelvin oversees TTS Group’s offices in Singapore and Vietnam, as well as representative offices in Australia and Myanmar. With over 23 years of experience in the traffic and transport sector, He has earned recognition as an international expert in transport planning, traffic engineering, and mobility solutions. A Chartered Engineer and Fellow of the Chartered Institution of Highways and Transportation, he actively engages with universities, mentoring students and sharing industry insights. Kelvin is also a trusted voice in the media, frequently providing expert commentary on traffic and SME leadership across Singapore and Vietnam.

Under Kelvin’s leadership, TTS Group has successfully executed large-scale projects across Asia, including the Sentosa Island Gateway Tunnel, North-South Expressway in Vietnam, the Hai Phong Expressway, and various urban traffic studies in Singapore. In 2014, he spearheaded the company’s expansion into Vietnam, strengthening TTS Group’s regional footprint and fostering international collaboration. With a team of over 70 professionals, Kelvin has guided the company through challenges including the COVID-19 pandemic, implementing a Business Continuity Plan that ensured operational stability and employee well-being.

TTS Group Pte Ltd has rapidly emerged as a leading traffic and transport consultancy in the Asia-Pacific, renowned for its innovation, technical expertise, and reliability. The company has delivered landmark projects including Hanoi’s Bus Rapid Transit systems, the Hai Phong Expressway, and the Yangon Elevated Expressway, transforming urban mobility across the region. Guided by its tagline, “Empower Solutions Through Intelligence,” TTS Group combines AI-driven transport technologies, data analytics, and a highly skilled multicultural team to provide sustainable, practical, and future-ready solutions. Its commitment to excellence, regional connectivity, and client-focused innovation has earned the company multiple awards, cementing its status as a trusted partner in shaping smart, efficient, and resilient transport systems throughout Asia.

The dual awards received at the Asia Pacific Enterprise Awards 2025 recognize Kelvin’s visionary leadership along with TTS Group’s commitment to innovation, excellence, and sustainable transport development. They highlight the company’s ability to deliver forward-looking solutions that empower communities, enhance mobility, and set a benchmark for intelligent transport consultancy across the Asia-Pacific region.

About Enterprise Asia

Enterprise Asia is a non-governmental organization in pursuit of creating an Asia that is rich in entrepreneurship as an engine toward sustainable and progressive economic and social development within a world of economic equality. Its two pillars of existence are investment in people and responsible entrepreneurship. Enterprise Asia works with governments, NGOs, and other organizations to promote competitiveness and entrepreneurial development, uplifting the economic status of people across Asia and ensuring a legacy of hope, innovation, and courage for future generations. Please visit https://www.enterpriseasia.org/ for more information.

About Asia Pacific Enterprise Awards

Launched in 2007, the Asia Pacific Enterprise Awards is the region’s most prestigious award for outstanding entrepreneurship, continuous innovation, and sustainable leadership. The Award provides a platform for companies and governments to recognize entrepreneurial excellence, hence spurring greater innovation, fair business practices, and growth in entrepreneurship. As a regional award, it groups together leading entrepreneurs as a powerful voice for entrepreneurship and serves as a by-invitation-only networking powerhouse. The program has grown to encompass 16 countries/ regions and markets all over Asia. For further information, please visit www.apea.asia.

New Global Beauty & Wellbeing Report unveils Emotional Wellbeing as the True Face of Beauty

New proprietary research from Oriflame redefines beauty as a powerful driver of wellbeing

STOCKHOLM, Oct. 8, 2025 /PRNewswire/ — Global beauty and wellbeing company, Oriflame, today releases its first Beauty & Wellbeing Report, revealing a major shift in how women around the world experience and define beauty. Based on a study of 3,500 women across seven countries, the report highlights the powerful role beauty plays in enhancing emotional wellbeing, self-confidence, and daily self-care.

The findings reveal that beauty today is not about chasing perfection, but about feeling emotionally supported, connected, and in control.

Speaking about the report, Anna Malmhake, CEO & President of Oriflame, said, “This report reaffirms what we’ve believed for decades: that beauty is a deeply emotional and empowering experience.

“Across the world, women are telling us that beauty rituals help them feel grounded, confident, and connected to themselves. That’s exactly the kind of beauty Oriflame stands for: accessible, effective, and emotionally meaningful.”

Key Findings:

  • Beauty & wellbeing are intricately connected: 95% of respondents say that they recognise a link between beauty and wellbeing, of those 42% see a strong link between the two.
  • Some 64% of women are most interested in personalised skincare and nutrition, more than any other health intervention.
  • Some 71% believe society overemphasises physical appearance, while individuals themselves place a greater value on self-confidence (47%) and happiness (36%). Some 43% of respondents connected beauty with both inner and outer qualities.
  • “Looking good makes me happy” was ranked as top choice for enhancing wellbeing but other benefits also included “feeling more positive about life”, “finding inner peace when they look good” and “feeling mentally refreshed after caring about their appearance”.

Find the full Beauty & Wellbeing Report at: www.oriflame.com

About Oriflame
As a globally renowned beauty and wellbeing company, Oriflame has empowered individuals since 1967 through its diverse portfolio of high-quality, innovative, and sustainable beauty and wellbeing products. It operates in over 60 markets.

About the Report
The Beauty & Wellbeing Report was commissioned by Oriflame and conducted independently by Toluna in November–December 2024. It surveyed women aged 18–75 across China, India, Mexico, Nigeria, Poland, Turkey, and the UK, examining how beauty habits intersect with emotional, physical, and social wellbeing.

 

Global Direct Selling Leader QNET Celebrates 27 Years, Showcasing Economic Impact and Announces Landmark Ghana Convention

PENANG, Malaysia, Oct. 8, 2025 /PRNewswire/ — QNET, a leading global lifestyle and wellness direct selling company, concluded its spectacular 27th-anniversary convention, V-Malaysia 2025, in Penang this week. The event, endorsed by Tourism Malaysia, welcomed over 10,000 independent distributors from more than 30 countries, serving as a powerful testament to the company’s global community and the significant economic benefits of its flagship events.

V-Malaysia 2025 Opening Ceremony
V-Malaysia 2025 Opening Ceremony

Held for the 13th consecutive year in Penang, the five-day convention underscored Malaysia’s position as a premier MICE (Meetings, Incentives, Conferences, and Exhibitions) destination. The partnership with Tourism Malaysia highlighted how major corporate events drive tourism, hospitality, and local economic activity.

A Global Stage for Innovation and Culture

The convention opened with a vibrant celebration of Malaysian culture at the SPICE Arena, featuring music, dance, and the appearance of ‘Wira’ and ‘Manja’, the Malayan sun bear mascots for the upcoming Visit Malaysia Year 2026 campaign. This fusion of global business and local tradition set the stage for an event focused on empowerment and connection.

Driving Entrepreneurship with Cutting-Edge Products

V-Malaysia 2025 served as the launchpad for QNET’s latest innovations designed to enhance personal wellness and lifestyle. Key launches included:

  • Harmoniq-Snooze: An adhesive bio-signaling patch designed to promote deeper, restorative sleep.
  • Qwik-Vibe: A clean, fast-acting oral strip for instant energy and mental focus.
  • The Bernhard H. Mayer® PTLuxe & Insignia Collections: New lines of platinum jewellery symbolizing resilience and style.

“For 27 years, QNET has been about empowering individuals to take control of their health and financial future,” said Trevor Kuna, Chief Marketing Officer at QNET. “V-Malaysia is the physical embodiment of our mission—a place where innovation meets culture, inspiring our entrepreneurs from Sub-Saharan Africa, the Middle East, Central Asia, and Southeast Asia to achieve more.”

Inspiring a Global Audience with a Story of Resilience

A defining moment of the convention was the keynote address by Sparsh Shah, a global youth icon, motivational speaker, and recording artist. Born with Osteogenesis Imperfecta (Brittle Bone Disease), Sparsh has overcome profound physical challenges to become a beacon of resilience and determination. He captivated the audience of thousands by sharing his life’s journey, weaving his powerful narrative with his original music. His message urged every participant to recognize their own unique potential and to harness an unstoppable mindset in the pursuit of their ambitions.

“Having Sparsh Shah share his incredible story was a deeply moving experience for our global community,” said Trevor Kuna, Chief Marketing Officer at QNET. “He embodies the very essence of RYTHM — rising above circumstances to inspire others. His presence reminded us all that entrepreneurship is not just about business success, but about the power of the human spirit to overcome any obstacle.”

A Legacy of Empowerment and Economic Partnership

Beyond the celebration, QNET used the occasion to announce its next major regional convention: V-Africa 2026, scheduled for the first quarter of 2026 in Ghana. This strategic move signals QNET’s commitment to fostering entrepreneurship and contributing to economic development in key growth markets.

“Our conventions are more than just meetings; they are economic partnerships with host nations,” Kuna added. “The success of V-Malaysia demonstrates how business tourism creates a positive ripple effect. We are thrilled to build on this legacy and bring the same energy and opportunity to Ghana with V-Africa 2026, further solidifying our commitment to empowering entrepreneurs across the African continent.”

V-Malaysia is rooted in QNET’s mission of RYTHM – Raise Yourself To Help Mankind, serving as a global platform for entrepreneurship, personal growth, and community.

For more information, visit www.qnet.net.

About QNET

QNET is a global lifestyle and wellness company that uses a direct selling business model to offer a wide selection of exclusive products designed to help people live healthier, more balanced lives. Since 1998, QNET’s innovative products and e-commerce-driven model have helped build a worldwide community of customers and microentrepreneurs, guided by the mission of RYTHM – Raise Yourself To Help Mankind.

QNET is a member of the Direct Selling Association in several countries, the Hong Kong Health Food Association, the Health Supplements Industry Association of Singapore, and more. The company is also a partner in global sports sponsorships, including as the official direct selling partner of Manchester City Football Club and the Confederation of African Football (CAF), underscoring its commitment to excellence and global reach.

Discover more at www.qnet.net.

Cyteph Completes Recruitment for Phase I Clinical Trial of CYT-101 in Patients with Recurrent Glioblastoma Multiforme Brain Cancer

BRISBANE, Australia, Oct. 8, 2025 /PRNewswire/ — Cyteph Pty Ltd, a biotechnology company developing novel immunotherapies for difficult-to-treat cancers, today announced that it has successfully completed recruitment for its first-in-human Phase I clinical trial of CYT-101.

CYT-101 is a novel off-the-shelf, HLA-matched CMV-specific T cell therapy for the treatment of glioblastoma multiforme (GBM) and other solid cancers. GBM is an aggressive brain cancer and one of the deadliest solid cancers in adults, with limited treatment options available.

The unique advantage of targeting CMV antigens on GBM cells is that they are detected on tumour cells while not found in surrounding healthy tissue. This characteristic allows for a highly targeted approach. By harnessing the power of allogeneic CMV-specific T cell therapy, CYT-101 has the potential to offer improved outcomes for GBM patients.

The Phase I study is being conducted in collaboration with Briz Brain & Spine and Newro Foundation and is evaluating the safety, tolerability, and preliminary signals of efficacy of CYT-101 in patients with recurrent GBM.

“We are pleased to have completed enrolment, reflecting the strong demand from clinical collaborators and patients for innovative treatment options for GBM,” said Professor Rajiv Khanna, Chief Scientific Officer and Founder of Cyteph. “This milestone marks an important step forward in our mission to bring transformative therapies to patients with few existing options.”

The Phase I trial follows participants through dose-escalation cohorts, with key readouts expected at the end of Q4 2025.

Results from this study will inform the design of subsequent clinical trials and support the continued development of CYT-101 as a novel treatment approach for glioblastoma and other high-unmet-need solid cancers.

“Completing recruitment is a critical milestone for any clinical program, and it underscores the dedication of our team, and the patients who make this research possible,” said Professor David Walker, neurosurgeon and spinal surgeon at Briz Brain & Spine and lead clinical investigator for the CYT-101 clinical trial.

The CYT-101 Phase I clinical trial is funded through Australia’s national biotech incubator CUREator.

Cyteph is a spin-out biotechnology company from QIMR Berghofer, a leading medical research institute based in Brisbane, Australia.

Media Contact: 

Bridie Barry
media@qimrb.edu.au
+61 428 592 194
http://www.cyteph.com/